ARC Group Announces Sponsors and Charitable Initiative for Capital Markets & M&A Forum 2026

ARC Group Announces Sponsors and Charitable Initiative for Capital Markets & M&A Forum 2026

KUALA LUMPUR, Malaysia, April 29, 2026 /PRNewswire/ -- ARC Group will host the Capital Markets & M&A Forum 2026: Malaysia Edition in Kuala Lumpur, continuing its role in delivering one of Southeast Asia's most established platforms for...

Daqo New Energy Announces Unaudited First Quarter 2026 Financial Results

Daqo New Energy Announces Unaudited First Quarter 2026 Financial Results

SHANGHAI, April 29, 2026 /PRNewswire/ -- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy" the "Company" or "we"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced its unaudited financial results...

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

JILIN, China, April 29, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary...

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

Piramal Pharma Limited Announces Results for Q4 and Full-year FY26

MUMBAI, India, April 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4)...

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total...

Joyson Electronics Announces Q1 2026 Results: Strong Orders of RMB 27.5 billion, Net Profit Attributable to Shareholders up Nearly 20% YoY

Joyson Electronics Announces Q1 2026 Results: Strong Orders of RMB 27.5 billion, Net Profit Attributable to Shareholders up Nearly 20% YoY

HONG KONG and NINGBO, China, April 27, 2026 /PRNewswire/ -- Joyson Electronics (699.HK) announced financial results for Q1 2026 on April 27. Revenue for the period reached approximately RMB 13.8 billion, profit attributable to shareholders was...

A Paradise Acquisition Corp. Announces Intention to Voluntarily Delist from The Nasdaq Stock Market LLC, Conditional Upon Consummation of its Pending Business Combination with Enhanced Ltd

A Paradise Acquisition Corp. Announces Intention to Voluntarily Delist from The Nasdaq Stock Market LLC, Conditional Upon Consummation of its Pending Business Combination with Enhanced Ltd

NEW YORK and HONG KONG, April 28, 2026 /PRNewswire/ -- A Paradise Acquisition Corp. (the "Company") today announced that, in connection with a proposed business combination (the "Business Combination") between the Company, A Paradise Merger Sub I,...

Republic Power Group Limited Announces Strategic Investment and Technology Access Agreement to Enter High-Growth RWA Tokenization and Blockchain Infrastructure Markets

Republic Power Group Limited Announces Strategic Investment and Technology Access Agreement to Enter High-Growth RWA Tokenization and Blockchain Infrastructure Markets

Transaction Marks First Phase of RPGL's Expanded Digital Asset Strategy, Providing Equity Stake in NVC Partners and Institutional-Grade RWA Platform Capabilities SINGAPORE, April 27, 2026 /PRNewswire/ -- Republic Power Group Limited (NASDAQ: RPGL)...

Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia

Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia

Phase 2 multicenter, open-label study (NCT07499102) will evaluate the safety and clinical efficacy of CK0801 Tregs in transfusion-dependent aplastic anemia. HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology...

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology

QINGDAO, China, April 27, 2026 /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 65
  • menu
    menu